Brain vs. body: new trial tests stronger drug dose against Drug-Chemo combo for tough lung cancer
NCT ID NCT07365410
Summary
This study aims to find the better first treatment for people with a specific type of lung cancer (EGFR-mutated NSCLC) that has spread to the brain. It will compare a higher dose of the targeted drug furmonertinib taken alone against a lower dose of the same drug combined with two chemotherapy drugs. The main goal is to see which approach is more effective at controlling the cancer and safer for 60 participants who have not had prior treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.